Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

MLA

Bhavnani, Sujata M., et al. “Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.” Antimicrobial Agents and Chemotherapy, vol. 60, no. 3, Dec. 2015, pp. 1600–07. EBSCOhost, https://doi.org/10.1128/AAC.02967-15.

APA

Bhavnani, S. M., Ambrose, P. G., Hammel, J. P., Rubino, C. M., & Drusano, G. L. (2015). Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations. Antimicrobial Agents and Chemotherapy, 60(3), 1600–1607. https://doi.org/10.1128/AAC.02967-15

Chicago

Bhavnani, Sujata M, Paul G Ambrose, Jeffrey P Hammel, Christopher M Rubino, and George L Drusano. 2015. “Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.” Antimicrobial Agents and Chemotherapy 60 (3): 1600–1607. doi:10.1128/AAC.02967-15.